Healthcare investors weighing the two global biopharma giants face a familiar dilemma in 2026: pay up for growth, or buy a discount that carries its own price. AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY) report strikingly different financial profiles in their fiscal 2025 annual reports — one richly valued with momentum behind it, the other cheap for reasons the market has already absorbed.
AbbVie’s growth engine runs on immunology, neuroscience and oncology. Skyrizi and Rinvoq, its two flagship immunology therapies, now drive roughly 42% of net revenues. The company sells primarily through large wholesale distributors — McKesson Corp (NYSE: MCK), Cardinal Health Inc (NYSE: CAH) and Cencora Corp (NYSE: COR) — which together facilitate nearly all of its U.S. pharmaceutical sales, a customer concentration that adds a layer of risk to the business. In 2026, AbbVie completed its acquisition of Apogee Therapeutics, expanding its reach by buying growth rather than waiting for it.
The numbers behind the premium: fiscal 2025 revenue came in at about $61.2 billion, up 8.6% year over year, with net income of roughly $4.2 billion and a net margin near 6.9%. The December 2025 balance sheet shows a debt-to-equity ratio of -21.1x, meaning total liabilities exceed shareholder equity, and a current ratio of about 0.7x. Free cash flow for the year reached nearly $17.8 billion.
The market prices all of this accordingly. AbbVie carries a market capitalization of $462 billion, with shares at $259.93 (52-week range: $190.75–$269.39). Trailing P/E stands at 73.96, forward P/E at 18.6x, price-to-sales at 7.2x, and the dividend yields 2.61% — a growth premium on full display.
Bristol Myers Squibb leads in oncology and hematology, anchored by Opdivo and Eliquis, and sells its medicines globally to a diversified mix of wholesalers, specialty pharmacies and government agencies. It is also navigating complex legal waters: a $6.7 billion lawsuit tied to its Celgene acquisition, and a patent-judgment suit brought by Cytokinetics (NASDAQ: CYTK) that could weigh on long-term financial planning.
Fiscal 2025 revenue was close to $48.2 billion, essentially flat with a 0.2% decline, while net income reached about $7.1 billion — a net margin of roughly 14.6%. The December 2025 balance sheet shows a debt-to-equity ratio of about 2.6x and a current ratio near 1.3x. Free cash flow came to roughly $12.8 billion.
The valuation tells the story of the risk: a $127 billion market cap, shares at $61.46 (52-week range: $42.52–$68.64), trailing P/E of 13.75, forward P/E of just 8.9x, price-to-sales of 2.6x and a dividend yield of 4.02%. The stock is cheap — and it appears cheap for a reason, with much of the difficulty already priced in.
AbbVie faces significant patent-expiry pressure, led by Humira’s loss of exclusivity and rising biosimilar competition. The Inflation Reduction Act (IRA) allows government price negotiation on several top-selling products, including Vraylar and Botox. Heavy concentration in Skyrizi and Rinvoq leaves the stock acutely sensitive to those franchises’ market dynamics, while the complex manufacturing of biologics carries risks of supply disruptions or regulatory hurdles.
Bristol Myers contends with the same revenue concentration and the inevitable sales decline when blockbusters like Eliquis or Opdivo lose patent protection. Pricing restrictions from government and private payers are tightening, with several key drugs already targeted for negotiation. Add to that significant litigation risk, high debt from past strategic acquisitions, and intense competition from Merck & Co Inc (NYSE: MRK) and Pfizer Inc (NYSE: PFE) across oncology and hematology.
For the current fiscal year, AbbVie’s net income is expected to surge to $14.6 billion from $4.2 billion, with revenue rising to $67.2 billion — and investors are watching for an FDA decision on a Parkinson’s treatment later this year. Bristol Myers is expected to grow revenue about 3% to $49.8 billion, with net income up more than 40% to $11.2 billion.
Bottom line: Bristol Myers’ newer growth brands are gaining traction and its pipeline holds interesting candidates, but the cheap valuation seems justified — priced-in difficulties soften the downside without making the stock an obvious buy, and the recovery timeline is hard to predict. AbbVie is pricier, though not outrageously so given the exceptional year it is having; long-term investors could do well to build a position even at a modest premium.